Vector Group Ltd logo

Vector Group Ltd (VGR)

Delisted
NYSE NYSE
Want to track VGR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Vector Group's stock up 6% after agreeing to be acquired by JT Group in $2.4 billion deal

Vector Group's stock up 6% after agreeing to be acquired by JT Group in $2.4 billion deal

Vector Group Ltd.'s stock VGR, +1.01% jumped 6% early Wednesday, after the diversified holding company said it's reached an agreement to be acquired by Japan's JT Group in a deal with a total equity value of about $2.4 billion.

Marketwatch | 1 year ago
Vector Group Ltd. (VGR) Q2 2024 Earnings Call Transcript

Vector Group Ltd. (VGR) Q2 2024 Earnings Call Transcript

Vector Group Ltd. (NYSE:VGR ) Q2 2024 Earnings Conference Call August 1, 2024 8:00 AM ET Company Participants Howard Lorber - President and CEO Nicholas Anson - President and COO, Liggett Group and Liggett Vector Brands Bryant Kirkland - SVP, Treasurer, and CFO Conference Call Participants Ian Zaffino - Oppenheimer & Co. Hale Holden - Barclays Karru Martinson - Jefferies Operator Welcome to Vector Group Ltd.

Seekingalpha | 1 year ago
Vector Group (VGR) Q2 Earnings and Revenues Surpass Estimates

Vector Group (VGR) Q2 Earnings and Revenues Surpass Estimates

Vector Group (VGR) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.30 per share. This compares to earnings of $0.32 per share a year ago.

Zacks | 1 year ago
4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

4D Molecular Therapeutics: R100 Vector Pushes Forward To Bring Q4 Of 2024 DME Data

A 4D Molecular Therapeutics, Inc. phase 2 PRISM study indicated that there was an 89% reduction in annualized injections when Wet-AMD patients were given a high dose of 4D-150; Phase 3 trial initiation is expected in Q1 2025. Results from the phase 2 SPECTRA study, using the same gene therapy 4D-150 for the treatment of patients with diabetic macular edema, expected in Q4 of 2024. The global diabetic macular edema market is expected to reach $3.93 billion by 2029.

Seekingalpha | 1 year ago
Nvidia Stock Could Rise 10-Fold On New $10 Billion Growth Vector

Nvidia Stock Could Rise 10-Fold On New $10 Billion Growth Vector

Nvidia stock has soared to about $1,200 a share — up some 287% since the chip designer's boffo May 2023 earnings report kindled generative AI fever.

Forbes | 1 year ago